PhotoCure - Agreement to mediate with DUSA

PhotoCure ASA, Galderma S.A, DUSA Pharmaceuticals Inc. and Queens University at Kingston, announced today that they have entered into a mediation agreement designed to facilitate resolution of the parties' potential patent disputes concerning PhotoCure and Galdermas Metvix® (methyl aminolevulinate) product.

PhotoCure ASA, Galderma S.A, DUSA Pharmaceuticals Inc. and Queens University at Kingston, announced today that they have entered into a mediation agreement designed to facilitate resolution of the parties' potential patent disputes concerning PhotoCure and Galdermas Metvix® (methyl aminolevulinate) product.
 
PhotoCure received 27 July 2004 approval from the U.S. Food and Drug Administration (FDA) for its novel product methyl aminolevulinate for photodynamic treatment of actinic keratosis (sun-induced, pre-cancerous skin condition). DUSA's product, the Levulan® Kerastick® has been approved for treatment of actinic keratoses using photodynamic therapy since September, 2000.
 
In order to avoid litigation, PhotoCure and Galderma agree to notify DUSA and Queens University 45 days in advance of launching methyl aminolevulinate in the US.

Associated companies: